Recently, new therapeutic classes have improved the management of diabetic nephropathy, which is the main cause of CKD and ESRD worldwide (3), particularly sodium glucose co-transporter 2 (SGLT2) inhibitors (4–8) and glucagon-like peptide-1 receptor (GLP-1R) agonists (9, 10). The gene discussed is GLP1R; the disease is chronic kidney disease.